Join our daily newsletter At The Bell to receive exclusive market insights
- Regeneus (RGS) has partnered with Australia’s Department of Defence (DoD) to develop the company’s Sygenus technology
- The DoD will provide $300,000 in funding to help optimise the Sygenus stell cell bioactive secretome formulation
- Regeneus intends to formulate the bioactive stem cell secretions into an analgesic gel, designed to treat battlefield injuries and pain
- Research into Sygenus technology will be conducted in partnership with a team at Adelaide University
- Regeneus is up four per cent and trading at 13 cents per share
Regeneus (RGS) has partnered with Australia’s Department of Defence (DoD) to develop the company’s Sygenus technology.
Under the partnership, the DoD will provide Regeneus with $300,000 in funding, to assist in the optimisation of a Sygenus stem cell bioactive secretome formulation. The goal is to take the secretions from stell cells and turn them into an analgesic gel, which can be applied to treat damaged tissue.
Both Regeneus and the DoD believe that the Sygenus gel could have applications in treating injuries and pain sustained in combat situations. In particular, it could provide an alternative to morphine, which is the main form of pain management for severe battlefield pain.
While morphine can help to treat acute injuries, it can reduce a casualty’s ability to remain capable on the battlefield and is also addictive. In comparison, Regeneus’ Sygenus gel is not addictive, does not impact a soldier’s abilities in combat, and is more potent and longer-lasting than morphine.
Regeneus’ Director of Clinical Development and Medical Affairs, Dr Sinéad Blaber, called the partnership an exciting development for the company.
“Sygenus is based on stem cell secretions, rather than the cells themselves. These bioactive secretions are far more stable than cells and can be formulated into a gel that can be carried as part of a soldier’s standard kit,” she said.
“As well as being a replacement for morphine for treating pain, the gel prevents blistering, reduces scarring, and can accelerate wound healing,” she added.
As part of the company’s development activities, research on Sygenus will be conducted in partnership with a team at the University of Adelaide. The team will be led by Professor Mark Hutchinson, who has been collaborating with Regeneus on Sygenus for the last five years.
Regeneus is up four per cent, trading at 13 cents per share at 3:54 pm AEST.
